Analysis of the cost-effectiveness of thrombolysis with alteplase in stroke;Análise de custo-efetividade da trombólise com alteplase no acidente vascular cerebral

Arquivos Brasileiros de Cardiologia

Volumn 95, Issue 1, 2010, Pages 12-20

  Araújo, Denizar Vianna ^a,c   Teich, Vanessa ^b   Passos, Roberta Benitez Freitas ^b   Martins, Sheila Cristina Ouriques ^c,d  

^a STATE UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b MedInsight Decisions in Health Care   (Brazil)

^c Instituto Nacional de Ciencia e Tecnologia para Avaliacao de Tecnologias em Saude (IATS) CNPq   (Brazil)

^d HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

Author keywords

Health care costs; Stroke; Tissue plasminogen activator

Indexed keywords

ACETYLSALICYLIC ACID; ALTEPLASE; CAPTOPRIL; HYDROCHLOROTHIAZIDE; PLACEBO; PROPRANOLOL; SARUPLASE; STREPTOKINASE; UROKINASE;

ADULT; AGED; ARTICLE; BRAIN HEMORRHAGE; BRAZIL; CLINICAL TRIAL; COMPARATIVE STUDY; CONSERVATIVE TREATMENT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DISABILITY; FEMALE; FIBRINOLYTIC THERAPY; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; RANKIN SCALE; STROKE; SYMPTOM; TREATMENT OUTCOME;

AGED; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; DIRECT SERVICE COSTS; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; MALE; MIDDLE AGED; QUALITY-ADJUSTED LIFE YEARS; SEX FACTORS; STROKE; THROMBOLYTIC THERAPY; TIME FACTORS; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 77956841084     PISSN: 0066782X     EISSN: 16784170     Source Type: Journal    
DOI: 10.1590/S0066-782X2010005000067     Document Type: Article

References (23)

1. Lessa I. Epidemiologia das doenças cerebrovasculares no Brasil. Rev Soc Cardiol Estado de São Paulo. 1999; 4: 509-18.
2. Bonita R. Epidemiology of stroke. Lancet. 1992; 339 (8789): 342-4.
3. Bamford J, Dennis M, Sandercock P, Burn J, Warlow C. The frequency, causes and timing of death within 30 days of a first stroke: The Oxfordshire Community Stroke Project. J Neurol Neurosurg Psychiatry. 1990; 53 (10): 825-9.
4. Brainin M, Olsen TS, Chamorro A, Diener HC, Ferro J, Hennerici MG, et al. Organization of stroke care: education, referral, emergency management and imaging, stroke units and rehabilitation. Cerebrovasc Dis. 2004; 17: 1-14. (Pubitemid 38067675)
5. Falcão IV, Carvalho EMF, Barreto KML, Lessa FJD, Leite VMM. Acidente vascular cerebral precoce: implicações para adultos em idade produtiva atendidos pelo Sistema Único de Saúde. Rev bras saúde matern infant. 2004; 4 (1): 95-102.
6. Heiss WD, Rosner G. Functional recovery of cortical neurons as related to degree and duration of ischemia. Ann Neurol. 1983; 14 (3): 294-301. (Pubitemid 13051232)
7. Spranger M, Steiner T, Schwab S, Hacke W. Acute ischemic stroke: revascularizing therapy. J Neurol. 1998; 245 (12): 567-72. (Pubitemid 28431889)
8. Wardlaw JM, Zoppo G, Yamaguchi T, Berge E. Thrombolysis for acute ischaemic stroke (Cochrane review). Oxford: Update Software; 2007.
9. Wardlaw JM, Warlow CP, Counsell C. Systematic review of evidence on trombolytic therapy for acute ischemic stroke. Lancet . 1997; 350 (9078): 607-14. (Pubitemid 27367793)
10. National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995; 333: 1581-7.
11. Hacke W, Kaste M, Fieschi C, Toni D, Lesaffre E, von Kummer R, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke: The European Cooperative Acute Stroke Study (ECASS). JAMA. 1995; 274 (13): 1017-25.
12. Hacke W, Kaste M, Fieschi C, von Kummer R, Davalos A, Meier D, et al. Randomized double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Lancet. 1998; 352 (9136): 1245-51. (Pubitemid 28470336)
13. Clark W, Wissman S, Albers G, Jhamandas JH, Madden KP, Hamilton S. Recombinant tissue-type plasminogen activator (Alteplase) for ischaemic stroke 3 to 5 hours after symptom onset: the ATLANTIS Study: a randomized controlled trial. JAMA. 1999; 282: 2019-26.
14. Post PN, Stiggelbout AM, Wakker PP. The utility of health states after stroke: a systematic review of the literature. Stroke. 2001; 32 (6): 1425-9.
15. Instituto Brasileiro de Geografia e Estatística (IBGE). Tábua completa de mortalidade - Sexo masculino - 2005. [Acesso em 2008 set 04]. Disponível em ftp://ftp.ibge.gov.br/Tabuas-Completas-de- Mortalidade/Tabuas-Completas-de-Mortalidade-2005/
16. Instituto Brasileiro de Geografia e Estatística IBGE. Tábua completa de mortalidade - Sexo feminino - 2005. [Acesso em 2008 set 04]. Disponível em ftp://ftp.ibge.gov.br/Tabuas-Completas-de-Mortalidade/ Tabuas-Completas-de-Mortalidade-2005/
17. Oster G, Huse DM, Lacey MJ, Epstein AM. Cost-effectiveness of ticlopidine in preventing stroke in high-risk patients. Stroke. 1994; 25 (6): 1149-56. (Pubitemid 24164753)
18. Sinclair S. Cost-utility analysis of tissue plasminogen activator therapy for acute ischaemic stroke: a Canadian healthcare perspective. Pharmacoeconomics. 2001; 19 (9): 927-36. (Pubitemid 32937943)
19. Instituto Brasileiro de Geografia e Estatística.IBGE, Pesquisa mensal de emprego: estimativas do mês de julho de 2007. [Acesso em 2008 set 4]. Disponível em http://www.ibge.gov.br/home/estatistica/ indicadores/trabalhoerendimento/pme-nova/defaulttab2.shtm
20. Gold MR. Cost-effectiveness in health and medicine. New York: Oxford University Press; 1996. p. 425.
21. Martinez-Vila E, Irimia P. The cost of stroke. Cerebrovasc Dis. 2004; 17: 124-9.
22. Christensen MC, Valiente R, Sampaio Silva G, Lee WC, Dutcher S, Guimarães Rocha MS, et al. Acute treatment costs of stroke in Brazil. Neuroepidemiology. 2009; 32 (2): 142-9.
23. Araújo DV, Tura BR, Brasileiro AL, Luz Neto H, Pavão AL, Teich V. Cost-effectiveness of prehospital versus inhospital thrombolysis in acute myocardial infarction. Arq Bras Cardiol. 2008; 90 (2): 91-8.